Rice Hall James & Associates’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.83M | Sell |
51,038
-3,094
| -6% | -$199K | 0.19% | 123 |
|
|
2026
Q1 | $3.05M | Sell |
54,132
-840
| -2% | -$54.7K | 0.17% | 130 |
|
|
2025
Q4 | $4.41M | Buy |
54,972
+2,043
| +4% | +$137K | 0.24% | 93 |
|
|
2025
Q3 | $2.58M | Sell |
52,929
-659
| -1% | -$40.8K | 0.14% | 139 |
|
|
2025
Q2 | $4M | Sell |
53,588
-495
| -0.9% | -$32.8K | 0.22% | 97 |
|
|
2025
Q1 | $3.44M | Buy |
54,083
+7,740
| +17% | +$526K | 0.2% | 111 |
|
|
2024
Q4 | $3.62M | Sell |
46,343
-384
| -0.8% | -$30.8K | 0.2% | 121 |
|
|
2024
Q3 | $3.76M | Sell |
46,727
-604
| -1% | -$48.8K | 0.2% | 113 |
|
|
2024
Q2 | $3.92M | Sell |
47,331
-533
| -1% | -$46.9K | 0.23% | 94 |
|
|
2024
Q1 | $4.09M | Sell |
47,864
-9,157
| -16% | -$719K | 0.23% | 91 |
|
|
2023
Q4 | $4.88M | Sell |
57,021
-812
| -1% | -$70.2K | 0.28% | 84 |
|
|
2023
Q3 | $5.18M | Buy |
57,833
+6,972
| +14% | +$622K | 0.33% | 75 |
|
|
2023
Q2 | $4.33M | Sell |
50,861
-7,853
| -13% | -$664K | 0.25% | 98 |
|
|
2023
Q1 | $4.86M | Buy |
58,714
+6,088
| +12% | +$493K | 0.28% | 88 |
|
|
2022
Q4 | $4.14M | Sell |
52,626
-29,997
| -36% | -$2.41M | 0.24% | 97 |
|
|
2022
Q3 | $6.12M | Buy |
82,623
+5,297
| +7% | +$380K | 0.35% | 67 |
|
|
2022
Q2 | $5.04M | Buy |
77,326
+681
| +0.9% | +$40.3K | 0.24% | 83 |
|
|
2022
Q1 | $4.84M | Buy |
76,645
+18,766
| +32% | +$1.02M | 0.19% | 101 |
|
|
2021
Q4 | $3.07M | Buy |
57,879
+14,647
| +34% | +$892K | 0.11% | 173 |
|
|
2021
Q3 | $3.05M | Buy |
+43,232
| New | +$2.73M | 0.11% | 144 |
|
|
2017
Q2 | – | Sell |
-117,978
| Closed | -$4.79M | – | 297 |
|
|
2017
Q1 | $4.79M | Sell |
117,978
-12,290
| -9% | -$480K | 0.23% | 101 |
|
|
2016
Q4 | $5.24M | Sell |
130,268
-303
| -0.2% | -$11.4K | 0.26% | 95 |
|
|
2016
Q3 | $4.73M | Buy |
130,571
+14,450
| +12% | +$496K | 0.25% | 98 |
|
|
2016
Q2 | $3.37M | Buy |
116,121
+1,645
| +1% | +$49.7K | 0.19% | 98 |
|
|
2016
Q1 | $4M | Buy |
114,476
+3,196
| +3% | +$103K | 0.23% | 97 |
|
|
2015
Q4 | $3.59M | Buy |
111,280
+48,303
| +77% | +$1.57M | 0.21% | 108 |
|
|
2015
Q3 | $2.04M | Buy |
+62,977
| New | +$2.37M | 0.13% | 166 |
|
|
2014
Q1 | – | Sell |
-302,993
| Closed | -$12.8M | – | 307 |
|
|
2013
Q4 | $12.8M | Buy |
302,993
+67,873
| +29% | +$2.79M | 0.92% | 44 |
|
|
2013
Q3 | $9.38M | Sell |
235,120
-22,663
| -9% | -$951K | 0.9% | 44 |
|
|
2013
Q2 | $10.7M | Buy |
+257,783
| New | +$10.4M | 1.05% | 35 |
|
Other funds holding HAE
AI
Rice Hall James & Associates's HAE Position: Q2 2026 in Review
Rice Hall James & Associates reduced its Haemonetics (HAE) stake by 5.7% in Q2 2026, selling an estimated $199K and leaving 51,038 shares worth $3.83M. The position accounts for 0.19% of the portfolio, ranked #123.
Rice Hall James & Associates first reported a position in HAE in Q2 2013 and has held it in 30 quarters since. The position peaked at $12.8M in Q4 2013. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Rice Hall James & Associates held 51,038 shares of Haemonetics worth $3.83M as of Q2 2026.
- Rice Hall James & Associates sold 3,094 Haemonetics shares in Q2 2026, an estimated $199K.
- Haemonetics made up 0.19% of Rice Hall James & Associates's portfolio in Q2 2026, its #123 holding.
- Rice Hall James & Associates first reported a position in Haemonetics in Q2 2013 and has held it in 30 quarters since.
- Rice Hall James & Associates's Haemonetics position peaked at $12.8M in Q4 2013.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.